ArticleFood science and biotechnology2016
Synthesis and controlled-release properties of chitosan/β-Lactoglobulin nanoparticles as carriers for oral administration of epigallocatechin gallate.
Article in Food science and biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 51 citations in OpenAlex.
- Enhancing the bioavailability and activity of natural antioxidants with nanobubbles and nanoparticles.Redox report : communications in free radical research · 2024Review
- Lipid-Based Nanoparticles in Delivering Bioactive Compounds for Improving Therapeutic Efficacy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Polymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges.Polymers · 2023Review
- Valorization of polyphenolic compounds from food industry by-products for application in polysaccharide-based nanoparticles.Frontiers in nutrition · 2023Review
- Preparation and characterization of high embedding efficiency epigallocatechin-3-gallate glycosylated nanocomposites.Current research in food science · 2023Article
- Nano-Strategies for Enhancing the Bioavailability of Tea Polyphenols: Preparation, Applications, and Challenges.Foods (Basel, Switzerland) · 2022Review
- Evaluating the Anticarcinogenic Activity of Surface Modified/Functionalized Nanochitosan: The Emerging Trends and Endeavors.Polymers · 2021Review
- Nanoencapsulation of Promising Bioactive Compounds to Improve Their Absorption, Stability, Functionality and the Appearance of the Final Food Products.Molecules (Basel, Switzerland) · 2021Review
- Application of Polyphenol-Loaded Nanoparticles in Food Industry.Nanomaterials (Basel, Switzerland) · 2019Review
- Food-grade Encapsulation Systems for (-)-Epigallocatechin Gallate.Molecules (Basel, Switzerland) · 2018Review
- An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery.Pharmaceutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A nano-sized double-walled carrier composed of chitosan and β-lactoglobulin (β-Lg) for oral administration of epigallocatechin gallate (EGCG) was developed to achieve a prolonged release of EGCG in the gastrointestinal tract. Carboxymethyl chitosan (CMC) solution was added dropwise to chitosan hydrochloride (CHC) containing EGCG to form a primary coating by ionic complexation. Subsequently, β-Lg was added to create a secondary layer by ionic gelation. The obtained EGCG-loaded chitosan/β-Lg nanoparticles had sizes between 100 and 500 nm and zeta potentials ranging from 10 to 35mV. FT-IR spectroscopy revealed a high number of hydrogen-bonding sites in the nanoparticles, which could incorporate EGCG, resulting in high encapsulation efficiency. EGCG incorporated in the primary coating was released slowly over time by diffusion from the swollen CMC-CHC matrix after the outer layer of β-Lg was degraded in the intestinal fluid. The sustained-release property makes chitosan/β-Lg nanoparticles an attractive candidate for effective delivery of EGCG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.